Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The extracted indication/mechanism-related claims are only partially supported by the provided label excerpts. Most other claims (pricing, insurance coverage, alternatives, and generic/patent effects) are not supported by the supplied prescribing information and therefore reduce overall alignment.
Category Scores
Accurate Statements
Suprep is a bowel preparation used before colonoscopies.
Section 1 INDICATIONS AND USAGE: "SUPREP Bowel Prep Kit is indicated for cleansing of the colon as a preparation for colonoscopy..."
Unsupported Statements
Suprep is a prescription medication used to clean out the colon in preparation for a colonoscopy or other intestinal procedures.
The provided label excerpt supports cleansing of the colon for colonoscopy in patients 12 years and older, but does not support the addition of "other intestinal procedures" and does not explicitly state "prescription medication" in the provided text.
Suprep works by causing the patient to have bowel movements that clear the colon of stool.
The provided label text included here explains an osmotic effect (water retained within the GI tract) but does not explicitly state that it works by causing bowel movements to clear stool.
Without insurance, a prescription for Suprep can range from approximately $50 to over $100 for a single dose.
Pricing/affordability estimates are not present in the provided prescribing information excerpts.
Prices for Suprep can differ significantly between retail pharmacies and online pharmacies.
Distribution-channel price variability is not present in the provided prescribing information excerpts.
Insurance plans often cover a portion of the cost of Suprep.
Insurance coverage statements are not present in the provided prescribing information excerpts.
Out-of-pocket expense for patients with insurance depends on the specific plan's formulary, deductible, and co-pay or co-insurance.
Payer/formulary/deductible/co-pay statements are not present in the provided prescribing information excerpts.
Other prescription bowel prep kits may have different price points than Suprep.
Comparative pricing of other products is not present in the provided prescribing information excerpts.
Non-prescription methods may exist as alternatives to Suprep, though their efficacy and patient tolerance can vary.
Alternative methods and comparative efficacy/tolerability are not present in the provided prescribing information excerpts.
Generic versions of some bowel preparation agents may be available and could offer cost savings.
Generic availability and cost-savings are not present in the provided prescribing information excerpts.
Patent expiration dates can influence the availability of generic versions and, consequently, the overall market price.
Patent/market-price relationships are not present in the provided prescribing information excerpts.
Contradictions
Important Omissions
Contraindications (not provided in the input), boxed warnings (not provided), and dosing/administration instructions (not provided).
Importance:
High
Warnings and precautions and adverse reactions were not provided in the input, so safety-related alignment cannot be assessed.
Importance:
Moderate
Drug interactions (not provided) and specific population precautions beyond the indication excerpt were not provided for evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The main label-alignment issues are non-label claims about pricing/coverage/alternatives and partially supported mechanism/indication scope. No direct contradictions to the provided label text were identified, but the absence of key safety-label domains in the supplied input prevents full safety verification.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims (pricing/insurance/alternatives/generics and patent effects) are not supported by the supplied FDA label excerpts; mechanism and indication scope are only partially supported.
Suggested Improvement
Restrict statements to the provided label-supported indication (colon cleansing for colonoscopy in patients 12+), and remove or clearly qualify non-label pricing/coverage/alternative/generic/patent-market assertions since they are not present in the supplied prescribing information.